Answers are grounded in this paper and cite their sources.
Digital health is a term that has become increasingly important in public health, biomedicine and social studies of health and illness. WHO’s “Global Strategy on Digital Health” for 2020–2025 (WHO, 2021) and global experiences of the COVID-19 pandemic brought on the growing adoption of digitally-mediated interventions and the various forms of digital health tools aimed at improving health and transforming treatment modalities. Studies conducted during and after the COVID-19 pandemic noted that the pandemic exacerbated the health inequities for previously disadvantaged groups and identified serious limitations to the adaptation of digital tools for drug services, including the limited acceptance and technical resources (Perri et al., 2021; Sultan, 2021).The promise of tech-assisted and internet-based technologies is to alleviate barriers in reaching marginalized communities including people who use drugs, people who live with disabilities and chronic infectious diseases and those who reside in remote rural areas. Yet, definitions of digital health and what it is designed to achieve, in which circumstances and for whose benefit, vary greatly. Critical public health scholars note that many digital health services are designed to boost personal responsibility and self-care practices, thereby upholding neoliberal economy and promoting the idea of an “empowered health consumer” (Lupton, 2014) – narratives which do not adequately respond to the needs and circumstances of many frequent drug users. Whether digital health is an unambiguously useful development, and how it can reinforce certain forms of exclusion and inequities, is of particular importance to consider in drug policy, drug treatment, harm reduction and other drug services. Against this background, the increased uptake of digitalization in health raises important questions of access, inclusion and privacy.In response to growing calls to adopt digital health, numerous apps and other digital tools have been developed to assist traditional service options, and to offer immediate crisis interventions. In Scotland, for example, a centralized app developed as part of the Digital Lifelines Program has shown promise in lowering barriers to accessing vital overdose prevention and related harm reduction services, including by providing digital devices such as smartphones, tablets and laptops to people who are likely to experience problems from drug use (Strachan et al., 2024). In another study from Russia, in the absence of such a centralized app, doctors used the Telegram messaging app to refer patients who use drugs to relevant emergency care and other medical services (Davitadze et al., 2024). However, there are several critical questions about access to digital health. Digital divide in the form of digital literacy such as the ability to use WHO-initiated eHealth, mHealth and telemedicine, as well as access to internet, and other technological infrastructure have been widely debated (Lupton, 2014). Here evidence suggest that collaborative design and implementation that is centered around user perspective is key to establishing trust especially in governmental digital health programs (Marent et al., 2018). Yet, specific guidelines to address structural conditions for these barriers, power imbalances in service design and delivery, as well as integration of lived experience for more nuanced care remain a marginal discussion in the literature. Against this background, there is still a significant gap in how drug policies could respond to the digitalization of health services on a larger scale.Global agendas addressing health inequities poorly define marginalized and vulnerable groups, often covering their participation under broad terms such as “health inclusion” (Tweed et al., 2021). While this could include people who use drugs and live with chronic infectious diseases, are in older age, experience homelessness, violence, belong to sexual or ethnic minorities, these groups are not always specified. In addition, most interventions and studies focus on overdose prevention and mortality, while more nuanced services targeting specific groups or different drug use patterns, such as recreational drug use among youth, or drug education are still underdeveloped (Loverock et al., 2023). There is an urgent need for services that thoughtfully address this intersectionality.Accessible, inclusive and transferable development of digital health also requires addressing the question of stigma and discrimination in health services. Reproduction of stigmatization and structural inequities through digital services and large electronic databases owned by tech industries are some of the concerns raised by drug scholars and activists (Lenton et al., 2025). These must be taken into consideration when developing digital health services that have traditionally prevented people from accessing drug services in the first place. Moreover, rapid development and decentralization of digital drug markets intensified the need to develop digital harm reduction responses and online health promotion strategies for wider audiences (van der Sanden et al., 2023). Studies show that in the absence of reliable digital health platforms and fragmented resources, many users refer to open-source Internet for medical advice, peer knowledge exchange and digital assessment of symptoms. These strategies are also adopted by some recreational drug users especially through peer-to-peer platforms (Boothroyd and Lewis, 2016; Rhumorbarbe et al., 2019). However, recent discussions note the role of private tech companies that capitalize on this digital data economy, and emphasize the need to understand how to navigate information control and algorithmic moderation of vital health promotion content (Gomes and Sultan, 2024).Most studies reporting on the new digital health programs focus primarily on the outcomes of testing, usability and reach (Labrique et al., 2020). However, the growth of digital data economy also sparked concerns around data sharing, data protection and data bias. For example, pharmaceutical market studies showed that the acceleration of digital health brought on new dynamics between government-supported digitalization efforts and the privatization of health data by big pharmaceutical companies (Gross and Geiger, 2023). In Europe, consumer applications became easier to implement, especially in the face of EU’s General Data Protection Regulation, and other confidentiality and data management guidelines in trading with countries outside of the EU. Ireland and Germany, for example, have struggled to reconcile collaborations between tech industry and local governments to improve access to digital health (Gross and Geiger, 2023). Drawing parallels to drug policy here requires further investigations on data protection in the development of national digital programs designed to assist with drug use related health problems. Care is needed to accommodate the sensitivity required in both reaching users digitally as well as maintaining long-term engagement while ensuring balance between extreme surveillance and the reverse effect, data marginalization (Gilman and Green, 2018).Transdisciplinary engagement with digital health foregrounds advocacy and user-driven design that mobilizes affected communities and thereby shapes the political outcomes of global health agendas (Davis, 2025). A particular emphasis here is on participation and human rights which in this case aid to strengthen the argument for developing community-centered approach. International guidelines for the implementation of digital health under the umbrella terms of inclusion, democratization of health and health justice do not directly translate into practical execution. In calling for transdisciplinarity at Drugs, Habits and Social Policy, we place a stronger emphasis on offering an equal platform to insights from professional practice alongside research and policy outputs. By widening the scope of studies, the journal aims to increase the field’s engagement with interdisciplinary research and a range of stakeholders. As editors, our mission here is to support this engagement, and widen the borders of social, medical and policy studies of drug use to allow better integration of different forms of knowledge and expertise of broader range of stakeholders. The limited reach of digital health interventions and services to marginalized communities and population groups without health-care privileges remains an important gap in research and practice. Here the question of health inequities becomes pertinent as the societal transitions toward digitalized health care further stretches the gaps between different social strata.One of the questions that arise in this discourse, is how to leverage digital technologies to enhance the quality of life for people who use drugs and redefine how health care is provided for underserved groups. Linking debates between digital health interventions and digital drug services, the most pressing questions now are: how efficiently can the local services adapt to the global guidelines, who is left out in the rapid digitalization of health interventions, what do privacy and data protection guidelines mean for the implementation of emergency drug services, what kind of technological advancements are inevitable for the near future and what does it mean for drug and social policy reforms in the long term? Among other questions, research is needed to uncover how rapid datafication of health can affect already disadvantaged groups who may be further isolated due to data marginalization, not possess required credentials to access health services or refrain from sharing sensitive personal information due to stigmatization. Further research needs to investigate implications of global digital health frameworks and their implementation in non-Western countries, especially, in comparison to techno-scientific advancements in liberal democracies and address the questions of data colonialism that arise in this relationship.
No takes yet. Share an insight, caveat, or question.
Sultan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: